09:25 A股开盘丨三大指数集体高开 沪指高开0.11%，深成指高开0.21%，创业板指高开0.07%，科创综指低开0.12%。 | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 000001 | 上证指数 | W/ | 4169.70 | 4.42 | 0.11% | | 399001 | 深证成指 | NA | 14397.68 | 30.78 | 0.21% | | 399006 | 创业板指 | 3 | 3390.69 | 2.35 | 0.07% | | 000680 | 科创综指 | No | 1853.18 | -2.21 | -0.12% | 2026.01.13 本文字数：596，阅读时长大约1分钟 作者 |一财阿驴 09:30AI应用方向延续强势，引力传媒7天6板，易点天下、卓易信息、迪安诊断、利欧股份、省广集团 均3连板。 恒生指数高开1.32%，恒生科技指数涨1.93%。科网股全线走强，阿里巴巴、阿里健康涨近5%，小鹏汽 车涨逾4%，金蝶国际、比亚迪股份涨逾3%。兆易创新H股上市高开45 ...

Group 1 - The Hong Kong Innovative Drug ETF managed by Penghua (159286) experienced a decline of 0.56% on January 12, with a trading volume of 73.0144 million yuan [1] - The fund's shares decreased by 5 million, bringing the total shares to 671 million, with a reduction of 10 million shares over the last 20 trading days [1] - The latest net asset value of the fund is calculated to be 602 million yuan [1] Group 2 - The performance benchmark for the Hong Kong Innovative Drug ETF is the National Index of Hong Kong Innovative Drugs, adjusted for exchange rates [1] - The fund has been managed by Penghua Fund Management Co., with fund managers Lin Song and Zhang Yuxiang [1] - Since its establishment on August 20, 2025, the fund has reported a return of -10.29%, while the return over the past month is 2.28% [1]

Group 1 - The National Medical Products Administration announced the approval of three Class I innovative drugs from Wuhan, marking the city's best historical performance in original drug innovation and research [1] - The approved drugs are classified as "global firsts" or "fill market gaps," highlighting their significance in the pharmaceutical industry [2] - The first drug, "Recombinant Human Albumin Injection (Rice)," developed by Wuhan Heyuan Biotechnology Co., utilizes genetic engineering to produce human-like albumin from rice, effectively turning rice into a "blood bank" [2] Group 2 - The second drug, "Children's Cow Bile Heat-Reducing Patch," developed by Jianmin Pharmaceutical Group, is the only approved traditional Chinese medicine gel patch for children in the last 20 years, filling a clinical gap in pediatric fever treatment [2] - The third drug, "Oral Hexavalent Recombined Rotavirus Live Attenuated Vaccine," developed by Wuhan Institute of Biological Products, is the world's first hexavalent rotavirus vaccine, capable of preventing six types of rotavirus-induced diarrhea, breaking the long-standing monopoly of foreign companies [2]

Core Viewpoint - The announcement indicates that the application for the上市 of the combination drug Ploglitazone Metformin extended-release tablets has been accepted by the National Medical Products Administration of China, representing a significant step in the company's innovative drug development [1] Group 1: Product Development - The product is a Class 1 innovative drug combining Ploglitazone and Metformin in an extended-release formulation, aimed at treating adult patients with Type 2 Diabetes Mellitus (T2DM) [1] - The intended indication is for patients with inadequate blood sugar control on Metformin monotherapy or those currently receiving a combination of Ploglitazone and Metformin [1] Group 2: Clinical Trial Results - Phase III clinical trials have demonstrated that Ploglitazone shows good efficacy and safety in initial treatment of T2DM patients and those with inadequate control on Metformin monotherapy [2] - The combination of Ploglitazone and Metformin has shown significant and sustained blood sugar-lowering effects with a lower incidence of hypoglycemia compared to Metformin alone [2] - The product has a low potential for drug interactions and does not require dosage adjustment for patients with mild to moderate renal impairment [2] Group 3: Market Strategy - The combination formulation simplifies treatment regimens and significantly improves patient adherence, leading to more effective blood sugar control [2] - The company is actively advancing the clinical development of a three-drug combination formulation consisting of Ploglitazone, Dapagliflozin, and Metformin to benefit more patients [2]

Macro and Strategy Research - The US manufacturing PMI has further declined in December 2025, marking the largest month-on-month drop since 2024, indicating a prolonged downturn for 10 months, while the service sector PMI remains strong, highlighting structural divergence in the US economy [2][3] - In China, the manufacturing PMI returned above the threshold in December 2025, with improvements in both supply and demand, while the non-manufacturing sector also showed unexpected recovery [3] Fixed Income Research - In December 2025, the central bank's liquidity net injection exceeded 800 billion, with money market rates remaining low, while the yield on 10Y government bonds rose by 1 basis point to 1.85% by the end of December [7][9] - The bond market is expected to maintain a range-bound pattern, with inflation and monetary policy acting as anchors for the upper and lower bounds of this range [9] Industry Research - The listing of Rebio Biotech on the Hong Kong Stock Exchange has increased attention on the small nucleic acid sector, with significant developments in the industry including the approval of new drugs and strategic partnerships [10][12][13] - The SW pharmaceutical index rose by 6.13% in the week of January 5-8, 2026, with all sub-sectors experiencing gains, indicating a strong market performance [13]

Investment Rating - The report indicates a positive investment outlook for the pharmaceutical sector, with the overall performance of the Shenwan Pharmaceutical and Biological Index increasing by 7.8% during the week, outperforming the Shanghai Composite Index which rose by 3.82% [2][3]. Core Insights - The pharmaceutical sector's overall valuation stands at 30.6 times earnings, ranking 10th among 31 Shenwan primary industries [5]. - The report highlights significant developments in the long-term care insurance system transitioning from pilot programs to full establishment during the 14th Five-Year Plan, with coverage reaching nearly 300 million people and fund expenditures exceeding 100 billion yuan by the end of 2025 [11]. - Notable advancements in drug commercialization include the launch of Novo Nordisk's oral GLP-1 weight loss drug Wegovy in the U.S., with monthly costs ranging from $149 to $299 for self-paying patients [13][14]. - Moderna has submitted a New Drug Application (NDA) for its seasonal flu vaccine mRNA-1010, showing promising efficacy results in clinical trials [15]. - Arrowhead has reported positive mid-stage results for its RNAi therapies ARO-INHBE and ARO-ALK7, demonstrating significant reductions in visceral and liver fat [16][17]. - GSK's hepatitis B drug Bepirovirsen has shown statistically significant functional cure rates in its Phase III trials [18]. - Recent approvals for innovative drugs in China include BeiGene's BCL-2 inhibitor and Sanofi's APOC3 siRNA drug, which addresses familial chylomicronemia syndrome [19][21]. Summary by Sections Market Performance - The Shenwan Pharmaceutical and Biological Index increased by 7.8%, ranking 6th among 31 Shenwan primary industries [2][3]. - Various sub-sectors showed positive growth, with medical devices and medical outsourcing leading with increases of 10.8% and 11.1%, respectively [5]. Industry Dynamics - The long-term care insurance system is set to expand significantly, with a focus on providing care for the elderly and disabled [11][12]. - The report emphasizes the importance of innovation in drug development, particularly in RNAi therapies and small nucleic acid drugs, which are gaining traction in clinical settings [16][18]. Company Developments - Significant partnerships and collaborations are highlighted, such as the $8.88 billion research collaboration between Insilico Medicine and Servier focusing on oncology [20]. - The report notes the successful commercialization of several new drugs, including BeiGene's and Sanofi's recent approvals, which are expected to impact market dynamics positively [19][21]. - The establishment of new companies and subsidiaries, such as the brain-computer interface subsidiary by Xinwei Medical, indicates a strategic shift towards innovative technologies in healthcare [22].

Group 1: Core Insights - WuXi AppTec (药明合联) has been selected as a representative in the "Top Ten Core Assets" in the Chinese pharmaceutical industry for 2026, highlighting its significance in the global market [1] - The company was established in 2021 as a joint venture between WuXi Biologics and WuXi AppTec, focusing on ADC CDMO services, and officially listed on the Hong Kong Stock Exchange in November 2023 [1] - WuXi AppTec has become the second-largest ADC CDMO supplier globally, with market share increasing from 1.8% in 2020 to 22% in the first half of 2025 [1][23] Group 2: Industry Background - The Chinese pharmaceutical industry has undergone a significant transformation over the past decade, evolving from a focus on generics to becoming a major contributor to global pharmaceutical innovation [3] - The rapid development of innovative drugs in China is driven by policy support, capital investment, and talent development, transitioning from cost and efficiency advantages to technological leadership [3] - The cumulative overseas licensing transaction value for innovative drugs has surpassed $130 billion, indicating China's shift from a generic drug manufacturing powerhouse to an innovative drug exporter [4] Group 3: ADC Market Dynamics - The ADC market is expected to grow significantly, with projections indicating a market size of $13.5 billion in 2024, reaching $150.2 billion by 2033, and ADC's share of the overall oncology market increasing from 5.2% to 27.3% during the same period [9] - The production of ADCs is complex and requires precise control, leading to high technical barriers that necessitate reliance on specialized CDMO services [10] - The global ADC outsourcing market is projected to grow from approximately $1.5 billion in 2022 to $11 billion by 2030, with a compound annual growth rate of 28.4% [10] Group 4: Company Performance and Strategy - WuXi AppTec offers integrated CRDMO services for ADCs, providing end-to-end solutions that reduce communication costs and enhance R&D speed for pharmaceutical companies [14] - The company's revenue for the first half of 2025 increased by 62.2% to 2.7 billion yuan, with net profit rising by 52.74% to 746 million yuan [14] - As of mid-2025, WuXi AppTec had executed 858 discovery projects, with 225 ongoing projects, including 103 in clinical and commercialization stages, capturing 30% to 35% of the global clinical pipeline market [17] Group 5: Future Outlook - The company is strategically expanding its ADC CDMO capacity in Singapore and China, with planned capital expenditures exceeding 1.5 billion yuan in 2024 and 2025 to meet growing market demand [24] - Revenue forecasts for WuXi AppTec indicate growth to 5.965 billion yuan in 2025, 8.058 billion yuan in 2026, and 10.422 billion yuan in 2027, with corresponding net profit projections of 1.555 billion yuan, 2.114 billion yuan, and 2.798 billion yuan [27] - The increasing demand for R&D and production outsourcing in the pharmaceutical sector is expected to stabilize and grow, contributing to the company's future profitability [26]

Core Viewpoint - WuXi AppTec (02268.HK) has been selected as one of the "Top Ten Core Assets" in the 2026 "Betting on China" list, representing the traditional Chinese medicine industry [2] Group 1: Company Overview - WuXi AppTec was established in 2021 as a joint venture between WuXi Biologics and WuXi AppTec, providing ADC CDMO services and officially listed on the Hong Kong Stock Exchange in November 2023 [3] - The company has become the second-largest ADC CDMO supplier globally, with market share increasing from 1.8% in 2020 to 22% in the first half of 2025 [3][39] Group 2: Industry Background - The rapid development of China's innovative pharmaceutical industry is attributed to policy guidance, capital support, and talent backing, transitioning from a "cost + efficiency" advantage to a technology-leading advantage [9] - The global ADC market is expected to grow significantly, with projections indicating a market size of $13.5 billion in 2024 and $150.2 billion by 2033, with ADC's share of the overall oncology market rising from 5.2% to 27.3% during the same period [18] Group 3: Business Performance - WuXi AppTec's revenue for the first half of 2025 increased by 62.2% to 2.7 billion yuan, with net profit rising by 52.74% to 746 million yuan [27] - The company has executed a total of 858 discovery projects since its inception, with 225 ongoing projects, including 103 in clinical and commercialization stages [30][31] - The company holds a 30% to 35% market share in clinical pipelines globally and has partnerships with 13 of the top 20 pharmaceutical companies [32] Group 4: Future Outlook - The company is expected to continue expanding its production capacity in Wuxi and Singapore, with capital expenditures exceeding 1.5 billion yuan in 2024 and 2025, aiming to double its production capacity by 2029 [39] - Revenue projections for WuXi AppTec are expected to reach 5.97 billion yuan in 2025, 8.06 billion yuan in 2026, and 10.42 billion yuan in 2027, with corresponding growth rates of 47.2%, 35.08%, and 29.35% [40][45] Group 5: Investment Thesis - Investing in WuXi AppTec is essentially a bet on the enhancement of global competitiveness of Chinese innovative drugs and the supporting CXO industry chain [52]

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index increased by 5.60%, ranking 8th among 31 primary industries, outperforming the CSI 300 index which rose by 2.18% [4][16] - The PE (TTM overall method, excluding negative values) for the pharmaceutical and biotechnology industry as of January 9, 2026, is 30.56x, up from 29.20x at the end of the previous period, indicating an upward valuation trend [4][21] - The top three sub-industries in terms of PE are vaccines (47.64x), hospitals (43.33x), and medical devices (39.44x), while pharmaceutical circulation has the lowest valuation at 15.42x [4][21] Industry Review - The report highlights significant developments in the pharmaceutical sector, including the release of the "Fourth Batch of Encouraged Generic Drug Catalog" aimed at optimizing the drug supply guarantee system and enhancing industry structure [6][26] - The report notes that 43 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to 2.779 billion yuan, with 8 companies increasing holdings by 20 million yuan and 35 companies reducing holdings by 2.799 billion yuan [4] Important Industry News - The National Health Commission and other departments released the "Fourth Batch of Encouraged Generic Drug Catalog," which includes 21 varieties and 47 specifications, focusing on clinical needs and disease burdens [26][27] - The NMPA announced measures to strengthen the supervision and management of entrusted drug production, aiming to enhance drug quality assurance levels [29][30] - The NMPA also optimized the review and approval process for urgently needed overseas drugs, encouraging simultaneous global development and submission [31][32] Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with strong pipeline differentiation, rapid clinical advancement, and robust overseas collaboration capabilities [7][8] - In the medical device sector, it recommends paying attention to companies with solid technical foundations and deep collaborations with leading hospitals and research institutions [8]

Group 1: Overview of Collaboration - HaiSiKe's PDE3/4 overseas authorization aims to achieve a win-win model by retaining Chinese rights while sharing overseas profits, accelerating the molecule's international deployment [2] - The company anticipates a period of international harvest and business development explosion in 2026, with ongoing expansion into oncology and large molecules [2] - The TYK2 project (FTP637) successfully entered overseas markets through a NEWCO model, completing phases 1-3 of clinical trials in about five years [3] Group 2: Key Collaboration Details - Transaction partner: AirNexis, led by Frazier Fund, with a transaction amount exceeding $1 billion, including an upfront payment of over $100 million and milestone payments of $955 million, along with double-digit sales sharing [3] - AirNexis is responsible for overseas clinical development and commercialization, while HaiSiKe retains rights for HSK39004 in China and global exclusive rights for combination formulations [3] - HaiSiKe's focus is on long-term benefits and overseas development efficiency while ensuring the protection of Chinese rights [4] Group 3: Clinical Progress and Differentiation - HaiSiKe is advancing both inhalation suspension and dry powder inhalation formulations, with the latter being globally leading [5] - The key phase 2 data in China is expected to be released in Q1 2026, with plans to initiate phase 3 studies for COPD in Q2 2026, aiming for NDA submission by late 2027 or Q1 2028 [5] - AirNexis plans to conduct population pharmacokinetics studies, with an NDA submission in the U.S. anticipated by Q4 2028 and potential approval by Q1 2030 [5] Group 4: Future Development and Opportunities - HaiSiKe is actively pursuing multiple projects in CNS and oncology, with hopes to initiate 1-2 key clinical trials in oncology by 2026 [7] - The company aims to independently conduct clinical research in the U.S. to generate proof-of-concept data before seeking external authorization partnerships, which could lead to larger transaction amounts [7] - Future collaborations may also involve platform-based R&D capabilities with leading multinational pharmaceutical companies or top-tier overseas investment funds [7] Group 5: Research and Development Focus - The R&D direction will focus on perioperative, respiratory, autoimmune, and oncology fields, expanding into biologics, ADCs, and cyclic peptides [8] - Short-term goals include advancing the approval of环泊酚 in the U.S., while mid-term goals involve achieving overseas market entries for DPP1 and PDE3/4 projects [8] - Long-term objectives include learning international market regulations and building a scalable overseas team [8]